导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.73% | 2627/4773 |
| 近一周 | -1.11% | 1696/5465 |
| 近一月 | -9.91% | 5270/5421 |
| 近一季 | 14.65% | 109/5231 |
| 近半年 | 3.02% | 984/4920 |
| 近一年 | -15.69% | 3770/4394 |
| 近两年 | 37.33% | 2018/2954 |
| 近三年 | 2.00% | 1895/2253 |
| 成立以来 | -20.60% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.47% 2308/4961 |
-2.05% 3383/5312 |
- - |
- - |
| 2025 | 19.53% 2208/4813 |
6.12% 677/3635 |
6.98% 407/4076 |
22.53% 1641/4524 |
-14.07% 4332/4813 |
| 2024 | -15.64% 2484/3463 |
-15.56% 2545/2808 |
-12.02% 2583/3014 |
23.47% 396/3129 |
-8.03% 2823/3463 |
| 2023 | -11.94% 1435/2656 |
-1.91% 1901/2280 |
-10.70% 2120/2385 |
2.92% 210/2515 |
-2.32% 457/2655 |
| 2022 | -25.26% 1303/2207 |
-11.08% 477/1919 |
-3.65% 1834/2016 |
-20.72% 1872/2113 |
10.02% 184/2208 |
| 2021 | -9.90% 1086/1822 |
-2.12% 584/1255 |
12.98% 300/1330 |
-10.80% 1240/1466 |
-8.65% 1588/1822 |
| 2020 | - - |
- - |
- - |
2.06% 1011/1164 |
6.33% 761/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 银华中证创新药产业ETF VS. 长安沪深300非周期A(740101) |